Related Experiment Videos

A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures

L E Gustavson1, S W Boellner, G R Granneman

  • 1Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.

Neurology
|April 1, 1997
PubMed

Insights

This study on tiagabine in children with complex partial seizures found that valproate significantly increased drug exposure and prolonged its half-life. Tiagabine was well tolerated in pediatric patients.

Area of Science:

  • Pharmacology
  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Complex partial seizures are a common form of epilepsy in children.
  • Antiepilepsy drugs (AEDs) can have altered pharmacokinetics in pediatric populations.
  • Understanding drug interactions is crucial for effective epilepsy management in children.

Purpose of the Study:

  • To assess the pharmacokinetics and safety of tiagabine in children with complex partial seizures.
  • To evaluate the impact of concomitant antiepilepsy drugs (AEDs) on tiagabine pharmacokinetics.
  • To compare tiagabine pharmacokinetics in children receiving valproate versus enzyme-inducing AEDs.

Main Methods:

  • An open-label study involving 25 children with complex partial seizures.
  • Administration of a single dose of tiagabine (approximately 0.1 mg/kg).
  • Concomitant use of individual AED regimens, including enzyme-inducing AEDs (carbamazepine, phenytoin) or valproate.

Main Results:

  • Tiagabine was well tolerated in all pediatric participants.
  • Children taking valproate showed significantly higher dose-normalized area under the plasma concentration-time curve (AUC) and longer half-life compared to those on inducing AEDs.
  • Oral clearance of tiagabine was approximately half in children taking valproate versus induced children.
  • Body size explained 40-50% of the variability in tiagabine clearance and volume of distribution.

Conclusions:

  • Valproate significantly increases tiagabine exposure and prolongs its elimination in children.
  • Tiagabine pharmacokinetics in children show similarities to adult patterns when considering concomitant AEDs.
  • Pediatric patients may exhibit higher tiagabine clearance and volume of distribution per body weight compared to adults.

Related Concept Videos